Compare NOTV & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NOTV | BCDA |
|---|---|---|
| Founded | 1974 | N/A |
| Country | United States | United States |
| Employees | N/A | 21 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8M | 12.9M |
| IPO Year | 1997 | N/A |
| Metric | NOTV | BCDA |
|---|---|---|
| Price | $0.28 | $1.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $1.50 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 981.7K | 54.8K |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 49.64 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $547,656,000.00 | N/A |
| Revenue This Year | $5.28 | N/A |
| Revenue Next Year | $5.42 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 511.19 | N/A |
| 52 Week Low | $0.22 | $1.00 |
| 52 Week High | $3.31 | $3.20 |
| Indicator | NOTV | BCDA |
|---|---|---|
| Relative Strength Index (RSI) | 47.14 | 45.22 |
| Support Level | $0.24 | $1.12 |
| Resistance Level | $0.41 | $1.31 |
| Average True Range (ATR) | 0.04 | 0.07 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 33.14 | 45.00 |
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).